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Studies have shown that vaccine vectors and route of immunization can differentially
activate different arms of the immune system. However, the effects of different HIV
vaccine immunogens on mucosal inflammation have not yet been studied. Because
mucosal sites are the primary route of HIV infection, we evaluated the cervico-vaginal
inflammatory cytokine and chemokine levels of Mauritian cynomolgus macaques
following immunization and boost using two different SIV vaccine immunogens. The
PCS vaccine delivers 12 20-amino acid peptides overlapping the 12 protease cleavage
sites, and the Gag/Env vaccine delivers the full Gag and full Env proteins of simian
immunodeficiency virus. We showed that the PCS vaccine prime and boosts induced
short-lived, lower level increases of a few pro-inflammatory/chemotactic cytokines. In
the PCS-vaccine group only the levels of MCP-1 were significantly increased above the
baseline (P = 0.0078, Week 6; P = 0.0078, Week 17; P = 0.0234; Week 51) following
multiple boosts. In contrast, immunizations with the Gag/Env vaccine persistently
increased the levels of multiple cytokines/chemokines. In the Gag/Env group, higher than
baseline levels were consistently observed for IL-8 (P = 0.0078, Week 16; P = 0.0078,
Week 17; P = 0.0156, Week 52), IL-1β (P = 0.0234, Week 16; P = 0.0156, Week 17;
P = 0.0156, Week 52), and MIP-1α (P = 0.0313, Week 16; P = 0.0156, Week 17;
P = 0.0313, Week 52). Over time, repeated boosts altered the relative levels of these
cytokines between the Gag/Env and PCS vaccine group. 18 weeks after final boost with
a higher dosage, IP-10 levels (P = 0.0313) in the Gag/Env group remained higher than
baseline. Thus, the influence of vaccine immunogens on mucosal inflammation needs to
be considered when developing and evaluating candidate HIV vaccines.
Keywords: HIV, SIV, vaccine, mucosal inflammation, pro-inflammatory cytokine/chemokine(s), non-human
primates
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INTRODUCTION

the 8 monkeys per vaccine group (7 in the Gag/Env group) were
run in duplicates and analyzed over the course of 11 time points.
Reported protein concentration was normalized against total
protein concentration for each monkey at each time point. Levels
of each cytokine/chemokine were compared between vaccine
groups and between time points within each group.

Inflammation promotes activation and localization of HIV
target cells, and elevated cervico-vaginal inflammation has
been associated with higher risk of HIV acquisition (1–6).
More recently, genital inflammation has also been shown
to reduce the efficacy of anti-HIV microbicides (7). Because
CD4+ T cells, an important part of the adaptive immune
system, are the main targets of HIV, developing an effective
HIV vaccine is more challenging than for other infectious
pathogens. Vaccines to infectious pathogens are designed to
generate long-lasting, antigen-specific immune memory that
can rapidly respond upon re-exposure to a specific pathogen.
However, activated CD4+ and CD8+ T cells produce many proinflammatory cytokines/chemokines that, in turn, may create
more targets for HIV infection (8–12). As a result, vaccineactivated T cells may potentially increase HIV target cells and
the susceptibility to HIV infection (13). The magnitude and
spectrum of immune responses generated by different candidate
HIV vaccines have been studied (14–18). Vaccine encoding
full-length Gag/Env would elicit a broader immune response
with higher magnitude than a vaccine delivering subsets of
peptides. Studies have also shown that live viral vaccine vectors
induced immune activation, which may enhance susceptibility
to HIV-1 infection (19–22). However, the effect of induction of
cervico-vaginal mucosal inflammation by parenterally/nasallydelivered SIV/HIV vaccine immunogens has not been reported.
Because vaccine immunogen-induced mucosal inflammation
may activate and attract HIV target cells, thus having opposite
effect on vaccine efficacy, in addition to evaluating the
immune responses generated by different vaccine immunogens,
evaluating the mucosal inflammatory cytokines induced by
different vaccine immunogens would be important. In this
study, we evaluated the changes of cervico-vaginal mucosal
inflammatory cytokines in response to immunization and boosts
with two SIV vaccines delivering two different SIV immunogens
in female cynomolgus macaques. One vaccine delivers full length
SIV Gag and Env proteins (Gag/Env vaccine) and the other
vaccine delivers twelve 20-amino-acid peptides overlapping the
12 SIV protease cleavage sites (the PCS vaccine) (23, 24).
We evaluated the inflammatory cytokine/chemokine levels in
the cervico-vaginal lavage (CVL) of female MCMs following
immunizations with the two vaccines. The immunogens were
delivered by vesicular stomatitis viral vector (VSV) and by
NANO formulations.

Preparation of rVSV Vaccines and NANO
Boosts
Generation of rVSVpcs and rVSVgag/env, as well as packaging
of the different SIVmac239 immunogens in nanoparticles were
performed as previously described (25, 26). Briefly, nucleotide
sequences of SIVmac239 (Los Alamos National Laboratory
HIV database) encoding 20 amino acids overlapping 12 PCS
were previously cloned in pATX VSV-G (rVSV vector), and
packaged into rVSVpcs virus. Each PCS peptide was also
encapsulated in nanoparticles of chitosan and dextran sulfate,
and then pooled together for a single dosage containing 50
µg of each peptide. The freeze-dried nanoparticle formulations
were stored at 4◦ C, and reconstituted in sterile water just before
the immunization. SIVmac239 full-length Gag and Env coding
sequences were previously prepared and packaged into rVSVgag
and rVSVenv viruses (rVSVgag/env), as previously described
(25). Separate DNA constructs coding for full-length Gag or
Env (pVAX1-Gag and pVAX1-Env) were packaged into separate
nanoparticles made of chitosan and tripolyphosphate to form the
NANOgag/env formulation.

Animal Model
Twenty-four colony-bred female Mauritian cynomolgus
macaques (Macaca facicularis) (MCMs), age 6–7 years old, were
used in the study [Bio-culture [Mauritius] Ltd.]. All animal
work and sample collection were conducted at Wisconsin
National Primate Research Center (WNPRC). Briefly, during
the course of the study, the non-human primates within the
same experimental group were pair-housed in the standard
stainless-steel primate cages with visual and auditory access to
other conspecifics. Rooms were maintained at 65–700 F with a
12-h light and 12-h dark cycle, starting at 0600 h. Daily standard
NHP chow with fruits or vegetables was provided with foraging
enrichment devices and activities provided at least weekly. All
animals were monitored for health or welfare issues at least
twice daily.
MHC (major histocompatibility complex) typing was
performed by the Wisconsin Non-human Primate Research
Centre Genetics Services as described previously (25). Those with
the same MHC haplotypes were grouped to form several MHCbased subgroups. To ensure the monkeys with different MHC
haplotypes are evenly distributed in 3 different experimental
groups the monkeys of each MHC-based subgroup were
randomly assigned to three experimental groups. Similarly,
animals were also screened for infections and constantly
monitored for hormone levels, menses schedule, age and weight.
Differences in hormone, menses levels and weights were also
considered when assigning monkeys to vaccine groups to ensure
even and random distribution. Our study comprised of three

MATERIALS AND METHODS
Study Design
Mucosal inflammatory cytokine and chemokine levels in the 24
female MCMs following immunization and repeated boosts were
evaluated using a custom 14-plex cytokine/chemokine panel. The
monkeys were divided into 3 groups of 8 monkeys that were
immunized with their respective vaccines: the control, PCS, and
Gag/Env vaccine group. Cervico-vaginal lavage (CVL) from each
monkey was collected and analyzed as samples of the mucosal
environment following each immunization (Figure 1). CVLs of
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FIGURE 1 | Immunization and sampling scheme. Prime and boosts were given to three groups of 8 female MCMs on the indicated weeks. CVL samples were
collected on all time points. Control group received rVSV vector and/or sterile water (black font), PCS group received rVSVpcs and/or NANOpcs (red font), Gag/Env
group received rVSVgag/env and/or NANOgag/env (blue font). rVSV, rVSVpcs, and rVSVgag/env were administered intramuscularly. NANOpcs and NANOgag/env
boosts were administered intranasally.

experimental groups, including the PCS vaccine group, the
Gag/Env vaccine group, and the control group.

frozen and shipped from Wisconsin to Winnipeg and stored in
a −800 C freezer until use.

Immunization

14-Plex Cytokine/Chemokine Assay

Immunization was performed as previously described (25).
Briefly, these monkeys were divided into 3 groups of 8
monkeys: the PCS vaccine group received rVSVpcs and
NANOpcs; the Gag/Env vaccine group received rVSVgag/env
and NANOgag/env; and the Control group received VSV virus
vector and sterile water boosts (Figure 1). One monkey in the
Gag/Env group exhibited signs of severe endometriosis that were
unrelated to immunization, leading to early euthanization of the
animal. Animals received a final dose of 2 × 107 plaque-forming
unit (pfu)/animal for the rVSV immunizations administered
intramuscularly via the quadriceps muscle, alternating between
left and right for each immunization. Specifically, 1.67 × 106
pfu/rVSVpcs type in the PCS group or 6 × 106 pfu of rVSVgag
and 6 × 106 rVSVenv in the Gag/Env group. A higher final dose
of 1 × 108 pfu/animal was used for Boost 4. All NANO boosts
were administered intranasally in 600 µL liquid (50 µg/PCS
peptide for the PCS group or total of 500 µg of plasma DNA
encoded Gag and Env for the Gag/Env group). The immunization
scheme consisted of prime (rVSV) at week 0 followed by boosts at
week 6 (rVSVs + NANOs), week 16 (NANOs), week 51 (rVSVs),
and week 72 (rVSVs) (Figure 1).

Cytokines/chemokines were quantified using a custom 14-plex
assay based on a previously published Bio-Plex assay method
with some modifications (25, 27). Bio-Plex R Amine Coupling
Kit (Bio-Rad, Canada) was used to couple 20 µg of capture
antibody for each cytokine/chemokine to 1.25 × 107 Bio-Plex
ProTM fluorescently-dyed magnetic COOH Beads, diluted to a
stock concentration of 5 × 106 beads/ml. The standard curves
were generated from eight 4-fold serial dilutions of the pooled
14 commercial cytokine/chemokine proteins diluted in 1% BSA
(Bovine Serum Albumin) in PBS and corresponding antibody
pairs (Table 1). To test for possible cross-reactivity between
capture antibodies purchased from different companies, a sevenplex assay was initially developed from same-sourced capture
antibodies. Subsequently, the other coupled bead types were
added to complete the 14-plex panel. Optimization of the final
standard curve range and overall assay consistency after the
addition of each bead type were attained by keeping the intraand inter-assay coefficient of variation (%CV) at <20 and 30%,
respectively, and the ratio of observed to expected protein
concentration (% recovery) for each cytokine at 70–130%, with
no bead counts of <50 per well, as recommended. Specificity of
the custom assay was validated using Bio-plex Pro 27-plex human
cytokine/chemokine protein standards (Bio-Rad) (Table 1).

Sample Collection
Samples were collected as previously described. Briefly, 2–4 ml
of CVL samples were collected weekly by non-traumatically
rinsing the vaginal lumen of sedated animals with phosphate
buffered saline (PBS) and gently flushing five times using the
same syringe. During days of immunization, CVL samples were
collected before the vaccination. The CVL samples were then

Frontiers in Immunology | www.frontiersin.org

Cytokine and Chemokine Quantification
The final panel consisted of 14 (pro- or anti-) inflammatory
cytokines/chemokines including Granulocyte Macrophage
Colony Stimulating Factor (GM-CSF), Interleukin (IL)-1α,
IL-1β, IL-6, IL-8, IL-10, IL-17, Interferon inducible protein 10
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(IP-10), Interferon gamma (IFN-γ), Monocyte Chemoattractant
Protein-1 (MCP-1), Macrophage Inflammatory Protein-1
alpha/beta (MIP-1α/β), Regulated on activation, normal T cell
expressed and secreted (RANTES)/CCL5, and Tumor Necrosis
Factor alpha (TNF-α) to quantify the inflammatory response in
the CVL samples (Table 1). Cytokines/chemokines that were not
detected in ≥ 50% of the samples were excluded from the heat
map analysis (TNF-α, IL-1α, and IL-10).
Briefly, 50 µl of capture antibody-coupled magnetic bead
complex in 1:600 dilutions (∼420,000 beads) were used per well
of a 96-well Bio-Plex ProTM 105 flat bottom plate. Fifty microliter
of undiluted CVL sample or standards were analyzed in the
assay with assay buffer as general diluent and blank controls.
Protein concentrations (pg/ml) were generated and reported by
the Bio-Plex Manager 6.1 software (Bio-Rad).

TABLE 1 | Protein standards and antibodies.
Name

Catalog No.

Vendor

Recombinant Human CXCL8/IL-8
Protein

208-IL

Novus/R&D System

Recombinant Human CCL5/RANTES
Protein

278-RN

Novus/R&D System

Recombinant Human GM-CSF
Protein

215-GM

Novus/R&D System

Recombinant Human Interferon
Gamma Protein

RIFNG

ThermoFisher Scientific

Recombinant Human IL-1
beta/IL-1F2

201-LB

Novus/R&D System

PROTEIN STANDARDS

Total Protein Quantification
Total protein concentration of each sample was used to
normalize cytokine/chemokine concentrations to account for
possible dilution variations introduced during CVL collection.
Total protein concentration (pg/mg)were quantified using
NanoOrange R protein quantitation kit (Thermo Fisher
Scientific, Waltham, MA) according to manufacturer’s protocol,
Briefly, standard BSA solution diluted with the NanoOrange
working solution was used to generate a standard curve.
Fluorescence was measured using a Spectrophotometer
Microplate Reader (Spectramax R , San Jose, CA). All samples
were run in duplicates with triplicate dilutions.

Recombinant Human IL-6 Protein

206-IL

Novus/R&D System

Recombinant Human IL-10 (aa
19-178) Protein

1064-IL

Novus/R&D System

Recombinant Human IL-17A Protein

317-ILB

Novus/R&D System

Recombinant Human CXCL10/IP-10

266-IP

Novus/R&D System

Recombinant Human CCL2/MCP-1
Protein

279-MC

Novus/R&D System

Recombinant Human CCL3/MIP-1
alpha protein

270-LD

Novus/R&D System

Recombinant Human CCL4/MIP-1
beta Protein

271-BME

Novus/R&D System

Recombinant Human TNF-alpha
Protein

210-TA

Novus/R&D System

Recombinant Human IL-1 alpha

200-LA

Novus/R&D System

ThermoFisher Scientific

CAPTURE ANTIBODIES
Human CXCL8/IL-8 Mab

M801

Statistical Analysis

Human CCL5/RANTES PAb

P230E

ThermoFisher Scientific

Graphing and statistical analysis were performed using
GraphPad Prism R 7 statistical software (San Diego, USA).
Analyses were done using Wilcoxon matched-pairs signed-rank
paired t-test and Mann-Whitney t-test, for matched pairs and
unpaired group comparisons, respectively. Technical duplicates
of n = 8 samples per group were used for all experiments. Data
was not corrected for multiple comparisons. P-values lower than
0.05 were considered to be statistically significant.

Rat Anti-Human GM-CSF- Unlabelled

10111-01

SouthernBiotech

Human IFNγ MAb

M700A

ThermoFisher Scientific

Human IL-1beta/ IL-1F2 Antibody

MAB601-500

Novus/R&D System

Human IL-6 Mab

M620

ThermoFisher Scientific

RESULTS

Human MCP-1/CCL2/JE Antibody

MAB679-500

Novus/R&D System

Human MIP-1α/CCL3Antibody

AF-270-NA

Novus/R&D System

Human MIP-1β/CCL4 Antibody

MAB271-100

Novus/R&D System

Human TNFα Mab

M303

ThermoFisher Scientific

Human IL-1 alpha/IL-1F1 Mab

MAB-200

Novus/R&D System

Human CXCL8/IL-8 MAb,
Biotin-labeled

M802B

ThermoFisher Scientific

Human CCL5/RANTES MAb,
Biotin-labeled

M230B

ThermoFisher Scientific

MCMs Primed With rVSV, rVSVpcs, or
rVSVgag/env Had Increased CVL
Cytokine/Chemokine Levels

10100-01

SouthernBiotech

Human/Primate IL-17/IL-17A
Antibody

MAB317-500

Novus/R&D System

Human IP-10/ CXCL10/CRG-2
Antibody

MAB266-500

Novus/R&D System

DETECTION ANTIBODIES

To evaluate the influence of vaccine immunogens on CVL
inflammatory mediators, we first assessed the fold change of the
cytokine/chemokine levels after prime and each boost (Figure 2).
We observed a general fold increase (FI) in the level of majority
of cytokines/chemokines in all 3 vaccine groups after prime.
Specifically at week 6, a 3-FI was observed in levels of IL-6 (3.19)
in the CVLs of MCMs immunized with VSV vector control. A
more than 3-FI in IFNγ (4.6), RANTES (4.8), GM-CSF (3.4),
MCP-1 (4.4), and IL-17A (3.3) levels were observed in the PCS
vaccine group. In the Gag/Env vaccine group, only a 2.4-FI was
observed for IL-6, and lower FIs were detected in the level of
other inflammatory mediators.

Frontiers in Immunology | www.frontiersin.org

Rat Anti-Human IL-10-Unlabelled

Rat Anti-Human GM-CSF-BIOT

10112-08

SouthernBiotech

Human IFNγ MAb, Biotin-labeled

M701B

ThermoFisher Scientific

Human IL-1beta/IL-1F2 Biotinylated
Antibody

BAF201

Novus/R&D System

Human IL-6 MAb, Biotin-labeled

M621B

ThermoFisher Scientific

Rat Anti-Human IL-10-BIOT

10110-08

SouthernBiotech
(Continued)
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Actual Levels of Multiple CVL
Cytokines/Chemokines Remained
Elevated Following Immunization and
Multiple Boosting in the Gag/Env Vaccine
Group Compared to Pre-immunization and
Pre-boost Levels

TABLE 1 | Continued
Human/Primate IL-17/IL-17A
Biotinylated Antibody

BAF317

Novus/R&D System

Human IP-10/CXCL10/CRG-2
Biotinylated Antibody

BAF266

Novus/R&D System

Human MCP-1/CCL2/JE Biotinylated
Antibody

BAF279

Novus/R&D System

Human MIP-1α/CCL3 Biotinylated
Antibody

BAF270

Novus/R&D System

Human MIP-1β/CCL4 Biotinylated
Antibody

BAF271

Novus/R&D System

Human TNFα MAb, Biotin-labeled

M302B

ThermoFisher Scientific

Human IL-1 alpha/IL-1F1
Biotin-labeled

BAF-200

Novus/R&D System

The levels of CVL cytokines/chemokines at the weeks following
prime and each boost were compared using Wilcoxon Paired
Matched t-test against the pre-immunization level and the
level at each boost (Figures 3–5). Significant increase in levels
of RANTES (P = 0.0156, week 1) and IL-10 (P = 0.0156,
week 6) were observed when cytokine/chemokine levels were
compared before and after prime with the VSV control
vector (Figures 3–5). A significant increase in levels of
MCP-1 (P = 0.0078, week 6) (Figure 4), was observed
following prime with rVSVpcs while no significant changes
in cytokine/chemokine levels were observed following prime
with rVSVgag/env.

CVL of MCMs in the Gag/Env Group Had
Increased Cytokine/Chemokine Levels
Following Multiple Boosting

Boosting With rVSV Vector and Water

A general decrease in CVL cytokines/chemokines was observed
following multiple boosting with the VSV vector control
(Figure 2). Overall, boosting with a combined regimen of
rVSVpcs/NANOpcs appeared to have only a modest influence on
CVL cytokine/chemokine levels. In comparison with the baseline
(week 0), Boost 1 with the PCS vaccine only induced ∼2-FI
of MCP-1 (2.23), IL-6 (2.27), and IFNγ (2.5). Boost 2 with
NANOpcs only resulted in a 4-FI (4.37) in MCP-1 level. Further
boosting with rVSVpcs/NANOpcs had little effect on majority of
the cytokines/chemokines, except for MCP-1 levels at week 72
(FI: 3.3). One week after a higher dosage of rVSVpcs at Boost
4, majority of the cytokines remained lower than baseline except
for a moderate FI in MCP-1 (2.73). By week 90, only the levels of
IP-10 (3.05), and MIP-1α (1.62) were higher than week 0.
In contrast, a more sustained and higher-than-baseline
increase in cytokine/chemokine levels was observed in the
Gag/Env vaccine group following multiple boosts (Figure 2).
After boost 1, FI values ranging from 3.3 to 5.9 in RANTES
(4.1), IL-1β (5.9), IL-8 (5.3), and MIP-1β (3.3) were observed
at week 16, while MIP1-α increased 2.5-fold. Following Boost 2
with NANOgag/env, most cytokine/chemokine levels remained
higher than baseline. FI values from 4.55 to 12.96 in RANTES
(6.64), IL-1β (12.3), IL-8 (4.55), MIP-1α (7.69), and MIP-1β
(4.63) were observed at week 17. Furthermore, the elevation of
MIP-1α (4.84), and MIP-1β (12.96) were maintained at week
51. A > 8-fold increase in IL-1β (14.33, 14.43), IL-8 (41.67,
4.7), MIP1α (6.68, 10.4), and MIP-1β (8.37) were observed
one and/or 21 weeks after Boost 3, with more than 40 FI in
IL-8 at week 52. Following a higher dosage of rVSVgag/env
boost, levels of several CVL inflammatory cytokines/chemokines
remained elevated compared to baseline (RANTES, 3.22; MCP1, 4.94; MIP1α, 5.11). Specifically, at week 73 an 11-FI in IFNγ
(11.33) and close to 5-fold increase in MCP-1 (4.94) levels were
observed, which were not evident after earlier immunizations.
Furthermore, the levels of IL-8 (3.7), MIP1α (9.67), IP-10 (9.64)
remained elevated at Week 90.

Frontiers in Immunology | www.frontiersin.org

Following boosting with the VSV control vector and water
(Boost 1), significant decreases were observed in the levels of
MCP-1 (P = 0.0156, week 7; P = 0.0391, week 16), GM-CSF
(P = 0.0469), IP-10 (P = 0.0391), MIP-1β (P = 0.0234), and IL17A (P = 0.0156) compared with their pre-Boost 1 levels at week
6 (Figures 3–5). Transient non-significant increases in the levels
of some cytokines were also noted. This decreased level of several
cytokines following Boost 1 in the control group was also evident
in comparison with their pre-immunization levels. The majority
of cytokine/chemokine levels following Boost 1 were significantly
lower than the pre-immunization levels. Specifically, GM-CSF
(P = 0.0313, week 7), RANTES (P = 0.0391, week 16), IP-10
(P = 0.0391, week 16), and IL-17A (P = 0.0234, week 16). As
expected, no changes were observed in the cytokine/chemokine
levels of the control group following sterile water boost (Boost 2),
except for the decrease in RANTES levels at week 17 (P = 0.0234)
in comparison with pre-Boost 2 levels at Week 16 (Figure 3).
In general, lower than baseline levels of RANTES (P = 0.0156),
MCP-1 (P = 0.0391), MIP-1β (P = 0.0391), and IL-17A
(P = 0.0156) were observed after Boost 3 in the control group
at week 17 while IP-10 levels remained lower until week 51
(P = 0.0078). No further significant changes were observed
after additional boosting with the control VSV vector except
for the significant decrease of GM-CSF (P = 0.0469) at week
72 (Figure 5). Although the levels of IP-10 (P = 0.0234, week
52; P = 0.0078, week 72) and RANTES (P = 0.0313, week 52)
remained lower than at baseline (Figure 3). Higher dose of VSV
vector seemed to have little influence on cytokine/chemokine
levels. The only significant increase was observed in IP-10 levels
(P = 0.0078) at week 90 in comparison to pre-Boost 4 levels
at week 72 (Figure 3). However, the elevated level of IP-10 at
week 90 was not significantly higher than its baseline levels, while
RANTES (P = 0.0156) and IP-10 (P = 0.0078) at week 73 and
MCP-1 levels (P = 0.0078) at week 90, were significantly lower
than week 0 (Figure 3).
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FIGURE 2 | Median cytokine/chemokine fold-change levels at each time point relative to group baseline (Week 0) in all 3 vaccine groups. The fold change was
calculated as the ratio of the concentration to the baseline where baseline was set to 0. Arrows indicate each immunization. Bar = Fold change, Shades of blue =
downregulated, Shades of red = upregulated. n = 8 monkeys/group (n = 7 for Gag/Env). Experiments were run in duplicates.

Boosting With the PCS Vaccine

Boosting With the Gag/Env Vaccine

Boost 1 (rVSVpcs + NANOpcs) appeared to only modestly
influence cytokine/chemokine levels of the PCS vaccine
group. Transient and non-significant increases in some
cytokines/chemokines were observed, while a significant
decrease was observed in RANTES levels (P = 0.0156) at week 16
compared to pre-boost levels at week 6 (Figure 3). Interestingly,
similar to the control group, RANTES levels remained lower
than baseline at week 17 (P = 0.0391) and week 51 (P = 0.0234)
(Figure 3). No significant changes were observed following
the NANOpcs boost with the exception of significantly higher
than baseline MCP-1 level (P = 0.0078) at both week 17 and 51
(P = 0.0234) (Figure 4).
Further boosting with rVSVpcs + NANOpcs appeared to
have little effect on majority of the cytokines/chemokines.
Compared with pre-Boost 3 levels, significant decrease in levels
of IL-17A (P = 0.0391), MCP-1 (P = 0.0234), and MIP-1α
(P = 0.0156) were observed at week 52 (Figures 3, 4). RANTES
level remained lower than that of the baseline (P = 0.0391)
at week 52 (Figure 3). Transient and non-significant increase
in some cytokines/chemokines and a significant increase in IP10 (P = 0.0078) levels at week 90 were observed following
boosting with a higher dose of rVSVpcs (Boost 4). However, IP10 level at week 90 in the PCS vaccine group was not significantly
higher than that of pre-immunization baseline (Figure 3). The
majority of cytokine/chemokine levels remained lower than
baseline, significantly lower level of RANTES was observed at
week 72 (P = 0.0078), week 73 (P = 0.0391), and week 90
(P = 0.0391) (Figure 3).

In contrast, boosting with rVSVgag/env + NANOgag/env (Boost
1) resulted in a general increase in the CVL cytokine/chemokine
levels except for the decrease in IL-6 (P = 0.0391) and IFNγ
(P = 0.0156) levels at week 7. IL-1β (P = 0.0234), IL-8
(P = 0.0078), and MIP-1α (P = 0.0313) levels were significantly
higher than the pre-immunization baseline (Figures 3, 4).
However, their levels at week 7 were not statistically significantly
higher than their levels at week 6 (pre-Boost 1). Significant
increase in RANTES levels (P = 0.0313) were observed 1 week
after the NANOgag/env boost (Boost 2) (Figure 3) while MCP1 levels (P = 0.0313) decreased at week 51 (Figure 4). Following
NANOgag/env boost, the levels of several cytokine/chemokines
remained significantly higher than baseline, including RANTES
(P = 0.0391), MIP-1α (P = 0.0156), IL-8 (P = 0.0078), and
IL-1β (P = 0.0156) (Figures 3, 4). Only GM-CSF level was
decreased and was lower (P = 0.0156) than baseline at week 51
(Figure 5).
Additional boost with rVSVgag/env + NANOgag/env
(Boost 3) resulted in a general increase in most
cytokine/chemokine levels, although only the increase in
MCP-1 levels were significant at week 72 (P = 0.0469) in
comparison with its pre-Boost 3 levels (week 51). Nevertheless,
significantly higher than baseline levels were maintained for
MIP-1β (P = 0.0156), IL-1β (P = 0.0156), IL-8 (P = 0.0156), and
MIP-1α (P = 0.0156) at week 52, and for MCP-1 (P = 0.0313)
and MIP-1α (P = 0.0313) at week 72 (Figures 3, 4). Following
a higher dose of rVSVgag/env (Boost 4) a general increase in
most of the CVL cytokines and chemokines were observed,
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FIGURE 3 | Significant changes in the CVL levels of IL-8, IP-10, RANTES, IL-17A, and IL-1β after immunization and multiple boosts analyzed using Wilcoxon
matched- pairs signed-rank paired t-test. Data presented as values from individual monkeys with median and range. Arrows indicate immunization. n = 8
monkeys/group (n = 7 for Gag/Env). Experiments were run in duplicates. *P < 0.05 and **P < 0.01.

Our study showed that immunization and boosts with
different vaccine immunogens influenced inflammatory
cytokines/chemokines in the cervico-vaginal mucosa. Higher
and more sustained increase in the levels of a broader spectrum
of inflammatory mediators was observed following repeated

particularly a significant increase in IP-10 levels (P = 0.0156) at
week 90 compared to its pre-Boost 4 levels (week 72) (Figure 3).
Furthermore, significantly higher than baseline levels of MIP1α (P = 0.0313, week 73) and IP-10 (P = 0.0313; week 90)
(Figures 3, 4) were observed.
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FIGURE 4 | Significant changes in the CVL levels of IL-6, MCP-1, MIP-1α, and MIP-1β after immunization and multiple boosts analyzed using Wilcoxon matchedpairs signed-rank paired t-test. Data presented as values from individual monkeys with median and range. Arrows indicate immunization. n = 8 monkeys/group (n = 7
for Gag/Env). Experiments were run in duplicates. *P < 0.05 and **P < 0.01.
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FIGURE 5 | Significant changes in the CVL levels of IFN-γ, GM-CSF, and IL-10 after immunization and multiple boosts analyzed using Wilcoxon matched- pairs
signed-rank paired t-test. Data presented as values from individual monkeys with median and range. Arrows indicate immunization. n = 8 monkeys/group (n = 7 for
Gag/Env). Experiments were run in duplicates. *P < 0.05.
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immunized with full Gag and Env immunogens showed increase
of a broader spectrum of inflammatory mediators with higher
magnitude than those immunized with short PCS peptides. This
elevation of multiple pro-inflammatory cytokines/chemokines
in the cervico-vaginal mucosa of the Gag/Env-immunized
MCMs persisted even at 18 weeks after the final boost; while
repeated immunizations with the short PCS peptides had little
persistent effect on the cervico-vaginal mucosal inflammatory
mediators. The persistent elevation of pro-inflammatory
mediators may have deleterious effect on potential efficacy
conferred by the Gag/Env vaccine. The immunogen-induced
mucosal inflammatory environment may tip the balance
between vaccine-induced anti-viral effect and vaccine-induced
susceptibility due to immune activation and the increase of
target cells, thus influence vaccine efficacy. The findings in this
study demonstrated that a candidate HIV vaccine may need
to consider immunogen induced mucosal inflammation and
immune activation.
Our study showed that both the VSV vector and the
immunogens appear to contribute to the magnitude and
spectrum of the increase of mucosal inflammatory mediators.
Although multiple cytokines/chemokines slightly increased in
the VSV vector-only control group after prime, only the level
of IL-6 was increased >3-fold, whereas, >3-fold increase of
five cytokines/chemokines (IFNγ, RANTES, GM-CSF, MCP1, and IL-17A) was observed in the MCM immunized with
rVSVpcs. The modest effect of rVSVgag/env on the mucosal
inflammatory cytokines/chemokines after prime could be due
to the slower replication of rVSVgag and rVSVenv than the
VSV and rVSVpcs. The unique characteristic of VSV as vaccine
vector to induce strong immunogen-directed humoral and
cellular immune responses (20, 28, 29) largely depends on its
fast replication (30). However, it has been demonstrated that
although flexible packaging capacity is a major advantage in using
VSV as a vaccine vector, adding inserts often led to slower viral
replication and therefore, low viral titres (29). It is possible that
due to carrying larger inserts, the rVSVgag/env initially induced
a weaker and delayed innate immune response after prime, as
seen in a previous study comparing cytotoxic T lymphocytes
(CTL) responses between VSV-Gag/Env and VSV-Gag only
immunization (20).
Our study also revealed that the influence of VSV vector on
mucosal inflammatory mediators was short-lived, as the increase
of cytokines/chemokines after the prime did not last, and further
boost with the VSV vector had little effect. On the other hand,
the apparent influence of immunogens on mucosal inflammatory
mediators seemed to last much longer as demonstrated by
the persistent elevation of multiple cytokines/chemokines 6–
8 months after boosting with the Gag/Env vaccine. Although,
when nano-formulated immunogens were used alone or
together with VSV-vectored immunogens to boost the immune
responses, the changes of the cervico-vaginal inflammatory
cytokines/chemokines are likely due to the host response to
the immunogens. Previous studies have shown that IgGs to
VSV were rapidly induced after immunization with VSV vector
and VSV-vectored immunogens, and neutralizing antibodies
against VSV are detectable even at 300 days post-immunization

exposure to the Gag/Env immunogens. This elevation of
multiple pro-inflammatory mediators in the cervico-vaginal
mucosa persisted 18 weeks after the final boost. In contrast, with
a more modest and transient increases in CVL inflammatory
cytokines/chemokines were evident following repeated exposure
to the PCS immunogen.

Relative Differences in CVL
Cytokine/Chemokine Levels Among the
Vaccine Groups Were Altered Following
Multiple Boosts
At pre-immunization baseline (week 0), control group CVL levels
of IP-10 (P = 0.0104, and P = 0.0006), IL-8 (P = 0.007), MCP-1
(P = 0.0205), MIP-1α (P = 0.0499, and P = 0.0019), RANTES
(P = 0.0104), MIP1β (P = 0.0207), and IL-17A (P = 0.0499)
were significantly higher than that of the PCS vaccine and/or the
Gag/Env vaccine groups (Figures 6–9), while only the level of
RANTES in the PCS vaccine group was higher than that of the
Gag/Env vaccine group (P = 0.0104) (Figure 8G). The increase of
CVL cytokine/chemokine levels after prime did not significantly
alter the relative differences among groups (time points showing
non-significant differences were omitted in figures). Similarly,
the significant increase in cytokine/chemokine levels in the
Gag/Env vaccine group following Boost 1 did not result in
alteration of relative levels of cytokines/ chemokines among the
three vaccine groups.
After boosting with nanoformulated immunogens, the relative
levels of CVL cytokine/chemokine levels between vaccine
groups were significantly altered. The increase of IP-10 after
NANOgag/env intranasal boost resulted in significant higher
levels in comparison to the PCS vaccine group at week 17
(P = 0.0207) (Figure 6F). Similarly, significantly higher levels
of IL-1β were observed in the Gag/Env vaccine group when
compared to that of the PCS group at the same time point
(P = 0.0379) (Figure 7D). Thus, boosting with nanoformulated
Gag/Env DNA increased cervico-vaginal mucosal IP-10 and IL1β levels.
On the other hand, the increase in MCP-1 following intranasal
NANOpcs boost resulted in significantly higher levels of MCP1 in the PCS vaccine group than that in the Gag/Env group
(P = 0.0471) at week 51 (Figure 7J). In the case of IL-8, an
increase in the levels of the Gag/Env group is observed over
time (Figures 6I–L), reaching significant differences with the
PCS group at week 52 (Figure 6J). Boost 3 also enhanced
the relative difference in IL-1β between the Gag/Env and PCS
groups (P = 0.0379) (Figure 7E). The repeated boosts also
altered relative levels of MIP-1α (Figures 8A–F), and RANTES
(Figures 8G–L) among the three groups.

DISCUSSION
Using a non-human primate model, our study is the first
to demonstrate distinct SIV immunogens induced different
mucosal inflammatory responses. SIV immunogens delivered
with VSV and nanoformulation differentially influenced
cervico-vaginal inflammatory cytokine/chemokine levels. MCMs
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FIGURE 6 | Significant differences in CVL levels of IP-10 and IL-8 among the 3 vaccine groups at different time points including Week 0 and 90 analyzed using MannWhitney t-test. Data presented as values from individual monkeys with median. (A–F) IP-10 (G–L) IL-8. n = 8 monkeys/group (n = 7 for Gag/Env). Experiments were
run in duplicates. *P < 0.05, **P < 0.01, and ***P < 0.001. Non-significant differences between groups were not included.
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FIGURE 7 | Significant differences in CVL levels of IL-1β and MCP-1 among the 3 vaccine groups at different time points including Week 0 and 90 analyzed using
Mann-Whitney t-test. Data presented as values from individual monkeys with median. (A–F) IL-1β (G–L) MCP-1. n = 8 monkeys/group (n = 7 for Gag/Env).
Experiments were run in duplicates. *P < 0.05 and **P < 0.01. Non-significant differences between groups were not included.
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FIGURE 8 | Significant differences in CVL levels of MIP-1α, and RANTES among the 3 vaccine groups at different time points including Week 0 and 90 analyzed using
Mann-Whitney t-test. Data presented as values from individual monkeys with median. (A–F) MIP-1α (G–L) RANTES. n = 8 monkeys/group (n = 7 for Gag/Env).
Experiments were run in duplicates. *P < 0.05, **P < 0.01, and ***P < 0.001. Non-significant differences between groups were not included.
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FIGURE 9 | Significant differences in CVL levels of IL-6, MIP-1β, and IL-17A among the 3 vaccine groups at different time points including Week 0 and 90 analyzed
using Mann-Whitney t-test. Data presented as values from individual monkeys with median. (A–C) IL-6 (D–I) MIP-1β (J,K) IL-17A. n = 8 monkeys/group (n = 7 for
Gag/Env). Experiments were run in duplicates. *P < 0.05 and **P < 0.01. Non-significant differences between groups were not included.

influence of immunogens on the cervico-vaginal inflammatory
cytokines/chemokines. Over the course of prime and boosts,
the PCS and Gag/Env vaccines differentially influenced cervicovaginal mucosal inflammatory cytokines/chemokines. Because

(28, 31). Thus, the short-lived effect of VSV vector on
the mucosal inflammatory mediators could be due to the
induced anti-VSV immune responses. However, the antiVSV vector immune responses did not appear to affect the
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Wisconsin, Division of Vice-Chancellor for Research and
Graduate Education.

only VSV-vectored immunogens were used for prime and
Boost 4, and only nano-formulated immunogens were used
for Boost 2, the influence of vector and immunogens can
be inferred.
Mucosal inflammation is not typically included in vaccine
efficacy evaluation. This study shows that evaluating the potential
effects of vaccine immunogens on mucosal inflammatory
cytokine/chemokine levels is important and that the balance
between vaccine-induced anti-viral immune responses
and vaccine-induced inflammatory response contributing
to susceptibility needs to be considered in HIV vaccine
development. However, since this study only examined the levels
of cytokines/chemokines produced after immunization and
boosting, this study was not able to determine which immune
cells are producing specific cytokines/chemokine at a given
time point. Future studies may examine mucosal tissue for cell
activation and proliferation, as well as the evaluation of systemic
inflammation following immunization.
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